Merck's Keytruda meets main goal in late-stage breast cancer study
Merck (MRK.N) said on Friday its blockbuster drug Keytruda, in combination with chemotherapy, met one of the main goals in a late-stage trial testing it in some breast cancer patients.
The study showed that the therapy was able to help clear all signs of tumor in patients compared to neo-adjuvant placebo plus chemotherapy.
Commentaires